Covering Disruptive Technology Powering Business in The Digital Age

Home > Archives > News > Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
image
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
image
September 13, 2021 News

 

Samsung Biologics, the world’s leading contract development and manufacturing organisation, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part of 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.

The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels, and local business leaders have joined forces with the British Embassy, Ewha Woman’s University, Financial Supervisory Service, to collectively thrive for a net-zero future. Frontier 1.5D is expected to address uncertainties associated with climate change by analysing the financial impact of climate change and climate response policies such as GHG reductions.

Samsung Biologics, as a business sector representative, will be closely monitoring, identifying and providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Science Based Targets (SBT) to determine risks and opportunities on climate change as well as the financial impact to translate these data into actions.

“We are proud and honored to be a part of the vital Frontier 1.5D initiative to ultimately redefine energy efficiency and reusable energy through the reduction of GHG emissions”, said John Rim, CEO at Samsung Biologics. “Alongside our core mission to bring a healthier and sustainable future for humanity, Samsung Biologics will support the development of mid to long-term climate change strategies and action plans as part of our decarbonisation efforts to achieve a net-zero future”.

About Samsung Biologics Co., Ltd.

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development, manufacturing and laboratory testing services. With proven regulatory approvals, the largest capacity and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. For more information, visit samsungbiologics.com.

(0)(0)